Scarica l'app Stockscreener
4.07
0.25%
0.01
Dopo l'orario di chiusura:
4.07
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.06
Aprire:
$4.05
Volume 24 ore:
20,651
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.45B
Reddito:
$842.96M
Utile/perdita netta:
$-185.63M
Rapporto P/E:
-7.7391
EPS:
-0.5259
Flusso di cassa netto:
$-228.52M
1 W Prestazione:
-0.73%
1M Prestazione:
+12.12%
6M Prestazione:
-3.10%
1 anno Prestazione:
+5.17%
Intervallo 1D:
$4.03
$4.0899
Intervallo di 1 settimana:
$4.03
$4.27
Portata 52W:
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
Confronta EVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.07 | 1.44B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-04-04 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-01-07 | Ripresa | Citigroup | Neutral |
Mostra tutto
Evotec Se Adr Borsa (EVO) Ultime notizie
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Annual General Meeting - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com India
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca
Investor Relations - Evotec
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Evotec Se Adr Azioni (EVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.18%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):